Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MD-120 in Japanese patients with depression
NCT04345471Phase 3Completed
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- May 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of desvenlafaxine in major depressive disorder (MDD) (3 arms), sponsored by Mochida Pharmaceutical Co., Ltd. Primary endpoints: Montgomery-Åsberg Depression Rating Scale at 8 weeks and Number of Participants With Adverse Events at 10 weeks. Started May 2020; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04345471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04345471.